The UK-listed ‌pharma’s shares fell 7% on reports of a Bristol Myers Squibb merger. A $380 bln ​deal would muddy CEO Pascal ...
The joint attempt ​to boost the currency is unlikely to have ‌lasting impact: Tokyo's fiscal policy is anathema to a stronger ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results